Evaluation of acute normovolemic hemodilution in patients undergoing intracranial meningioma resection

A quasi-experimental trial

Lei Yang, MMa, Hui-Hui Wang, MMb, Fu-Sheng Wei, MMc, Long-Xian Ma, MMc*

Abstract
The aim of this study was to evaluate the safety of acute normovolemic hemodilution (ANH) for patients undergoing intracranial meningioma resection.

Eighty patients (aged 48–65 years) with American Society of Anesthesiologists physical status I–III undergoing intracranial meningioma resection were included in this prospective observational study. The patients were randomly divided into group A (ANH group), which underwent a combination of ANH and intraoperative cell salvage (ICS), and group B (control group), which underwent ICS alone. The study parameters were recorded as baseline values before blood drainage (T0), after blood drainage (T1), and before (T2) and after (T3) transfusion of autologous blood.

When intraoperative blood loss was <2000 mL, the mean volume of homologous blood transfused in group A patients was 100.8 ± 82.3 mL compared with the 190.0 ± 91.8 mL in group B. Reduction in homologous blood used in group A was statistically significant (P < .05). In group B, 15.1% patients received homologous blood, whereas only 5.9% patients received homologous blood in group A. The difference in heart rate between both groups at different time points was statistically nonsignificant (P > .05). The mean hemoglobin and hematocrit levels at T1 and T2 in group A were lower than in group B (P < .05). The prothrombin time and activated partial thromboplastin time in both groups were prolonged significantly after T2 (all P < .05), but were all within normal range. There were no significant differences in postoperative hospital stay, mortality, and postoperative infection between the 2 groups.

For patients undergoing excision of intracranial meningioma, ANH is an effective procedure to reduce the need for allogeneic transfusions.

Abbreviations: ANH = acute normovolemic hemodilution, APTT = activated partial thromboplastin time, BP = blood pressure, CVP = oxygen saturation, central venous pressure, Hct = hematocrit, HR = heart rate, ICS = intraoperative cell salvage, MAP = mean arterial pressure, PT = prothrombin time.

Keywords: acute normovolemic hemodilution, blood transfusion, intracranial surgery, meningioma

1. Introduction
Extensive surgical procedures for intracranial meningiomas, especially for deep-seated meningiomas, are often associated with marked blood loss, resulting in the transfusion of allogeneic blood products.[1] Although the potential problems regarding transfusions are well known, transfusion of homologous blood, which increases the risk of infectious diseases and immunological complications, is also a persistent concern.[2–4] To minimize allogeneic blood transfusions, some blood conservation strategies have been introduced and are in routine clinical use. Acute normovolemic hemodilution (ANH) is one such technique that has been used as an alternative to homologous blood transfusions in neurosurgery procedures such as craniosynostosis and spinal procedures.[5–8] ANH with autologous transfusion, which involves the intraoperative removal and storage of whole blood before surgical blood loss, could significantly decrease the requirement for homologous blood during and after surgery.[9] Although a majority of neurosurgical procedures are associated with unwar- ranted blood loss, there are few studies concerning ANH use in patients undergoing intracranial surgery and a lack of evidence regarding its benefits or its ability to prevent complications.[10] The present study was designed to determine the safety of ANH for patients undergoing intracranial meningioma resection.

2. Methods
2.1. Study design and participants
The protocol and design of this quasi-experimental trial study was approved by the ethical and scientific committee of The First
2.2. Anesthesia and intervention

All patients underwent a standardized general anesthetic technique. Cardiac electrical activity, blood pressure (BP), heart rate (HR), mean arterial pressure (MAP), oxygen saturation, central venous pressure (CVP), end-tidal carbon dioxide (ETCO₂), and bispectral index were routinely monitored. Anesthesia was induced with an intravenous administration of propofol, remifentanil, sufentanil, and penehyclidine (0.01mg/kg), midazolam (0.01mg/kg), and rocuronium (0.06mg/kg). When the trachea was intubated, ventilation was mechanically controlled to maintain P₅⁰₇CO₂ at 30 to 40 mm Hg. Anesthesia was controlled to maintain PETCO₂ at 30 to 40 mm Hg. Anesthesia was induced with an intravenous administration of propofol, remifentanil, sufentanil, and penehyclidine (0.01mg/kg), midazolam (0.01mg/kg), and rocuronium (0.06mg/kg). When the trachea was intubated, ventilation was mechanically controlled to maintain P₅⁰₇CO₂ at 30 to 40 mm Hg. Anesthesia was stabilized with propofol, remifentanil, sufentanil, and cisatracurium. Bis was controlled within a range of 40 to 60.

Patients in group A underwent ANH in which whole blood was collected from the internal jugular vein (20mL/min) and an equal volume of blood collected was more than 600 to 800mL, the blood was washed and stored in labeled bags containing acid-citrate-dextrose at room temperature. Retransfusion was recommended protocols. Trained executive operators performed the blood salvage process. The negative pressure was less than 20 cmH₂O. Retransfusion was started in the ANH group when the main tumor resection of tumor was completed or if Hb was <7 g/dL (T₂), and after retransfusion (T₃) in group A. In group B, the same parameters were measured 10 minutes after anesthesia induction (T₀), before surgery (T₁), before transfusion of autologous blood (T₂), and after transfusion of autologous blood (T₃). Details regarding postoperative hospital stay, mortality, and postoperative infection were also collected for both groups.

2.4. Statistical analysis

Descriptive analyses of variables were used to summarize the data. Normally distributed variables were expressed as mean± standard deviation and were compared with Student t test. The chi-square or Fisher exact test was used to compare proportions between the 2 groups. All reported P values were 2 sided, and P values <.05 were considered statistically significant. The statistical analysis was performed with the Statistical Package for the Social Sciences version 18.0 software (SPSS Inc, Chicago, IL).

3. Results

The patient characteristics are shown in Table 1. There were no significant differences in age, sex, weight, duration of surgery, and intraoperative blood loss between 2 groups (P>.05). When intraoperative blood loss was <2000 mL, the mean volume of frozen plasma transfused in group A was 100.8±82.3 mL, compared with the 190.0±91.8 mL in group B. Reduction in homologous blood (red blood cell and frozen plasma) used in group A was statistically significant (P<.05). In group B, 15.1% patients received homologous blood, whereas, only 5.9% patients received homologous blood in group A. Six of the patients lost >2000 mL of blood and could not avoid allogeneic transfusions through ANH (Table 2).

MAP, HR, and CVP at various time points in both groups are summarized in Table 3. When compared to baseline values (T₀), a significant reduction in CVP was observed in both groups at T₂ (P<.05). MAP in group A was lower than in group B at T₁ (P<.05). The difference in HR between both groups at the different time points was statistically nonsignificant (P>.05). The mean Hb and Hct levels at T₁ and T₂ in group A were lower than in group B (P<.05); however, the mean Hb and Hct levels at T₁–T₂ were lower than at T₀ in the 2 groups (P<.05) (Table 4). PT and APTT in both groups were prolonged significantly after T₂ (all P<.05), but were all within normal range. PT and APTT at T₃ were significantly shortened in group A (P<.05). There were no significant differences in postoperative hospital stay, mortality, and postoperative infection between the 2 groups (Table 5).

4. Discussion

In neurosurgery, during the excision of intracranial meningiomas, the extensiveness of the surgical procedure is considered a

| Group | Age, y | Sex, male/female | Weight, kg | Hemoglobin, g/L | Duration of surgery, h | Blood loss, mL |
|-------|--------|-----------------|------------|-----------------|------------------------|---------------|
| A     | 50.5±9.1 | 20/20       | 61.4±6.2  | 120.1±11.5     | 5.2±0.9              | 865.2±656     |
| B     | 48.7±8.9  | 22/18       | 63.1±6.8  | 126.0±9.4      | 4.9±1.1              | 965.2±356     |

2
major problem and is associated with a significant amount of blood loss due to the high vascular nature of the tumor. Moreover, hemostasis is usually difficult to achieve, especially in deep-seated meningiomas, and blood transfusion is often required. Among the blood conservation strategies currently in use, ANH is a safe technique and is regarded as the most effective for several reasons. First, ANH eliminates inherent delay between donation and operation, and is a cost-effective technique with no administrative or storage costs. Furthermore, ANH refers to no additional personnel costs and no use of expensive equipment being the technique to provide fresh blood for use. Thus, of the alternative methods for blood conservation techniques widely used, ANH is the simplest and most cost effective. A lot of research showed that ANH could decrease the requirement for allogeneic blood transfusions. The present study also added new evidence that ANH could effectively save the use of homologous blood. Reduction in homologous blood transfusion in the ANH patients was statistically significant.

The majority of studies explaining the mechanisms of ANH involve elevation of cardiac performance and decreasing afterload. Evidence in experimental studies have also suggested that brain and coronary flow increased, although several studies recommended that surgery patients with coronary disease were not suitable for hemodilution. In addition, 1 study has been

| Table 2 |
| --- |
| Perioperative allogeneic transfusions. |

| Allogeneic transfusions | Blood loss < 2000 mL | Blood loss ≥ 2000 mL |
| --- | --- | --- |
| Red blood cell transfusion, n, % | Group A (n = 34) | Group B (n = 33) | Group A (n = 6) | Group B (n = 7) |
| Red blood cell transfusion, U | 0 (0.0) | 2 (6.0)* | 2 (33.3) | 4 (67.1) |
| Frozen plasma, n, % | 0 | 1.2 ± 1.1* | 3.2 ± 1.7 | 3.5 ± 1.9 |
| Frozen plasma, U | 2 (5.9) | 3 (9.1) | 4 (66.7) | 3 (42.9) |
| Frozen plasma, U | 100.8 ± 82.3 | 190.0 ± 91.8* | 407.5 ± 93.1 | 485.0 ± 162.1 |

*P < .05 for group A compared with group B.

| Table 3 |
| --- |
| MAP, HR, and CVP at various time points in the 2 groups. |

| Parameter | Group | T0 | T1 | T2 | T3 |
| --- | --- | --- | --- | --- | --- |
| MAP, mm Hg | A | 93.6 ± 8.3 | 87.3 ± 11.1 | 88.8 ± 10.4 | 89.9 ± 11.1 |
| B | 96.7 ± 8.9 | 96.1 ± 11.5 | 97.1 ± 9.4 | 97.1 ± 10.4 |
| HR, bpm | A | 64.3 ± 8.2 | 69.6 ± 7.8 | 65.7 ± 8.1 | 66.1 ± 6.7 |
| B | 66.9 ± 7.0 | 67.8 ± 8.8 | 66.6 ± 7.6 | 71.1 ± 6.5 |
| CVP, mm Hg | A | 9.5 ± 1.9 | 8.9 ± 2.9 | 7.7 ± 2.3* | 9.3 ± 2.4 |
| B | 8.9 ± 3.3 | 9.2 ± 3.2 | 7.1 ± 3.3* | 8.9 ± 3.6 |

Values are expressed as mean ± standard deviation. CVP = central venous pressure; HR = heart rate; MAP = mean arterial pressure.

*P < .05 for group A compared with group B.

| Table 4 |
| --- |
| Hb, Hct, PT, and APTT at various time points in the 2 groups. |

| Item | Group | T0 | T1 | T2 | T3 |
| --- | --- | --- | --- | --- | --- |
| Hb, g/L | A | 127.5 ± 8.1 | 108.4 ± 12.6 | 75.4 ± 9.2 | 96.1 ± 9.5 |
| B | 128.7 ± 8.9 | 123.5 ± 13.5 | 79.1 ± 8.8 | 96.7 ± 9.4 |
| Hct | A | 36.5 ± 2.6 | 32.1 ± 1.3 | 23.5 ± 3.8 | 30.9 ± 3.7 |
| B | 36.9 ± 2.0 | 33.8 ± 1.8 | 24.6 ± 3.6 | 31.1 ± 2.6 |
| PT, s | A | 12.5 ± 1.3 | 12.7 ± 1.2 | 14.7 ± 1.9 | 13.8 ± 1.5 |
| B | 12.2 ± 1.4 | 12.6 ± 1.3 | 15.4 ± 1.7 | 15.6 ± 1.7 |
| APTT, s | A | 32.3 ± 5.2 | 31.9 ± 5.4 | 40.2 ± 5.5 | 33.1 ± 4.2 |
| B | 31.9 ± 5.3 | 32.1 ± 5.2 | 41.1 ± 5.3 | 36.9 ± 4.6 |

Values are expressed as mean ± standard deviation. APTT = activated partial thromboplastin time, Hb = hemoglobin, Hct = hematocrit, PT = prothrombin time.

*P < .05 for group A compared with group B.

†P < .05 for T1, T2, or T3 compared with T0.

| Table 5 |
| --- |
| Postoperative hospital stay, infection, and mortality in the 2 groups. |

| Group | Postoperative hospital stay, d | Postoperative infection | Postoperative death |
| --- | --- | --- | --- |
| | Yes | No | % | Yes | No | % |
| A | 12.3 ± 3.4 | 5 | 35 | 12.5 | 2 | 38 | 5.0 |
| B | 12.2 ± 6.1 | 6 | 34 | 15.0 | 3 | 37 | 7.5 |
reported that cardiac output in anesthetized participants with Hct levels of 20% to 25% increased by 16% to 50%.[19] In present study, ANH was performed with a target Hct of 32%. The removal of autologous blood units and hemodilution was accompanied with hemodynamic stability and we did not observe any significant changes in HR.

There is no consensus on the benefits of hemodilution in neurosurgical procedures,[17,20] although it has been reported using in pediatric craniosynostosis surgeries.[21] ANH is an alternative technique for obtaining autologous blood that removal of blood from patient, with simultaneous replacement of normovolemia using cell-free fluid. Colloid is the commonly used cell-free fluid, which is still the potential risk factor of hypersensitivity reaction. Our study was performed in adults and analyzed enormous hemodynamic parameters to confirm conclusions for guiding clinical practice. We also found no significant differences in postoperative hospital stay, mortality, and postoperative infection between the 2 groups.

The main limitation of this study is the small sample size. The insufficient sample size and short-term follow-up may limit the significance of the study, and is insufficient to detect small differences in outcome. Furthermore, the volume of ANH may also influence the outcome. Our study failed to assess the association between volume ANH and clinical outcomes. Some studies reported that large volume hemodilution was associated with adverse complications.[22,23] Finally, although the strict exclusion criteria was assumed to minimize biases, the potential bias factors, such as population characteristics, may not be completely eliminated in our study.

5. Conclusions
For patients undergoing excision of intracranial meningioma, ANH is an effective procedure to reduce the need for allogeneic transfusions. However, the small sample size precludes final conclusions about the safety for routine use.

Acknowledgments
We would like to express our gratitude to our coworkers and the patients who participated in this study.

References
[1] Naqash IA, Draboo MA, Lone AQ, et al. Evaluation of acute normovolemic hemodilution and autotransfusion in neurosurgical patients undergoing excision of intracranial meningioma. J Anaesthesiol Clin Pharmacol 2011;27:54–8.
[2] Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. Br J Anaesth 2005;95:33–42.
[3] Weisskopf RB. Hemodilution and candles. Anesthesiology 2002;97:773–5.
[4] Spahn DR, Casutt M. Eliminating blood transfusions: new aspects and perspectives. Anesthesiology 2000;93:242–55.
[5] Di Rocco C, Tamburrini G, Pietrani D. Blood sparing in craniosynostosis surgery. Semin Pediatr Neurol 2004;11:278–87.
[6] Oppitz PP, Stefani MA. Acute normovolemic hemodilution is safe in neurosurgery. World Neurosurg 2013;79:719–24.
[7] Daif AA, Hassan YM, Ghareeb NA, et al. Cerebral effect of acute normovolemic hemodilution during brain tumor resection. J Neurosurg Anesthesiol 2012;24:19–24.
[8] Epstein NE. Bloodless spinal surgery: a review of the normovolemic hemodilution technique. Surg Neurol 2008;70:614–8.
[9] Jarnagin WR, Gonen M, Manthal SK, et al. A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection. Ann Surg 2008;248:360–9.
[10] Davies MJ, Cronin KD, Domaingue C. Haemodilution for major vascular surgery—using 3.5% polygeline (Haemaccel), Anaesth Intensive Care 1982;10:265–70.
[11] Che J, Tian M, Ding G, et al. Effects of cell salvage on erythrocyte 2,3-diphosphoglycerate and G-6-PD levels and phosphatidylserine expression. Int J Lab Hematol 2013;35:385–92.
[12] Dong P, Che J, Li X, et al. Quick biochemical markers for assessment of quality control of intraoperative cell salvage: a prospective observational study. J Cardiothorac Surg 2014;9:86.
[13] Zhou ZF, Jia XP, Sun K, et al. Mild volume acute normovolemic hemodilution is associated with lower intraoperative transfusion and postoperative pulmonary infection in patients undergoing cardiac surgery—a retrospective, propensity matching study. BMC Anesthesiol 2017;17:13.
[14] Oriani G, Pavesi M, Oriani A, et al. Acute normovolemic hemodilution. Transfus Apher Sci 2011;45:629–74.
[15] Spahn DR, Goodnough LT. Alternatives to blood transfusion. Lancet 2013;381:1855–65.
[16] Bennet J, Haynes S, Torella F, et al. Acute normovolemic hemodilution in moderate blood loss surgery: a randomized controlled trial. Transfusion 2006;46:1097–103.
[17] Korosue K, Heron RC, Ogilvy CS, et al. Comparison of crystalloids and colloids for hemodilution in a model of focal cerebral ischemia. J Neurosurg 1990;73:576–84.
[18] Messmer K. Hemodilution. Surg Clin North Am 1975;55:659–78.
[19] Zauder HL, Stehling L. Acute normovolemic hemodilution. J Clin Anesthet 2000;12:498.
[20] Myburgh JA. “Triple h” therapy for aneurysmal subarachnoid haemorrhage: real therapy or chasing numbers? Crit Care Resusc 2005;7:206–12.
[21] Paccagnella F, Longatti PL, Neri A, et al. Autotransfusion technic in surgery of craniosynostoses in children [in Italian]. Minerva Anestesiol 1989;55:165–8.
[22] Grant MC, Resar LM, Frank SM. The efficacy and utility of acute normovolemic hemodilution. Anesth Analg 2015;121:1412–4.
[23] Zhou X, Zhang C, Wang Y, et al. Preoperative acute normovolemic hemodilution for minimizing allogeneic blood transfusion: a meta-analysis. Anesth Analg 2015;121:1443–55.